Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n ¼ 457; ramipril, n ¼ 444) X65 years of age with systolic blood pressure (SBP) X140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (À14.0 and À5.1 mm Hg, respectively) were non-inferior (Po0.001 for both values) and superior to ramipril monotherapy (À11.6, À3.6 mm Hg; P ¼ 0.02, Po0.01, respectively). More patients achieved BP control with aliskiren (42%) than ramipril (33%; Po0.01). At week 36, fewer patients receiving aliskiren-based therapy required add-on treatment with hydrochlorothiazide or amlodipine (P ¼ 0.01 and 0.048, respectively). Tolerability was similar, but more patients receiving ramipril reported cough (Po0.001). In elderly patients with systolic hypertension, aliskiren proved to be more effective and better overall anti-hypertensive therapy compared to ramipril.
Introduction
Hypertension is a major public health issue that is currently under-recognized and undertreated, and the most frequent type of uncontrolled hypertension in the elderly is systolic hypertension.
1,2 The incidence of hypertension increases with advancing age; 30% of Americans are hypertensive, and twothirds of Americans aged X65 years are hypertensive. 2 More than two-thirds of patients will require two or more agents from different drug classes to achieve the recommended blood pressure (BP) of o140/90 mm Hg (o130/80 mm Hg for diabetic and hypertensive high-risk patients). 3, 4 Elevated systolic BP (SBP) is associated with greater risk of overall mortality, coronary heart disease, stroke, congestive heart failure and renal failure than diastolic BP (DBP). 5, 6 Treatment of isolated systolic hypertension, mostly in patients 460 years old, has been shown to reduce the incidence of stroke by 36%, non-fatal myocardial infarction or cardiovascular death by 27%, cardiovascular disease by 32% and heart failure by 49%. 7, 8 Several recent large, randomized, placebo-controlled trials of drug therapy that targeted systolic hypertension in the elderly have shown dramatic reductions in cardiovascular end points and mortality. [8] [9] [10] [11] [12] However, despite evidence to suggest that even small reductions in SBP are associated with improved outcomes, clinicians appear to be far less aggressive and less successful at controlling SBP compared with DBP. 3, 4, 6 The idea of reducing BP by blocking the renin-angiotensin-aldosterone system at its origin by direct inhibition of renin has existed for more than 30 years, and angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers have shown efficacy for improved cardiovascular outcomes in elderly patients. [13] [14] [15] Aliskiren, an oral direct renin inhibitor, has been shown to be effective in lowering arterial BP as monotherapy or in combination with other anti-hypertensive drugs. [16] [17] [18] To date, aliskiren has not been prospec-tively evaluated in a controlled study in elderly patients with systolic hypertension. The purpose of this study (Aliskiren for GEriatric LowEring of SyStolic Hypertension: The AGELESS trial) was to compare the efficacy and safety of the direct renin inhibitor aliskiren compared with the ACE inhibitor ramipril for the treatment of essential systolic hypertension in elderly patients.
Materials and methods

Design overview
This was a 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study. After a 1-to 2-week washout period for patients receiving anti-hypertensive medication, they were randomized to treatment with either aliskiren 150 mg per day or ramipril 5 mg per day (Figure 1a Ramipril was used as a comparator as it is a commonly prescribed ACE inhibitor and at a dose of 10 mg is safe and well tolerated in elderly patients with cardiovascular disease. 19 A dose of 300 mg of aliskiren was selected as it was previously found to be effective and well tolerated in elderly patients with hypertension. 20 
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Setting and participants
Men and women aged X65 years with essential hypertension (msSBP X140 and o180 mm Hg and mean sitting diastolic BP (msDBP) o110 mm Hg) were eligible for enrolment at 100 centres in the United States. Patients with a history of severe cardiovascular or cerebrovascular disease or other life-threatening medical conditions were excluded. Patients were excluded if serum sodium or potassium was less than the lower limit of normal or if serum potassium was X5.5 mEq l À1 . Patients with evidence of severe renal impairment with an estimated glomerular filtration rate o30 ml/min per 1.73 m 2 as measured by the Modification of Diet in Renal Diseases formula, 21 or heavy proteinuria (urinary albumin to creatinine ratio 43500 mg g À1 ) or evidence of the nephrotic syndrome were excluded. The study was performed in compliance with the Guidelines for Good Clinical Practice and the Declaration of Helsinki Principles (2002) of the World Medical Association and received approval from the local and central institutional review boards/independent ethics committees/research ethics boards for each centre. All patients provided written informed consent before the start of the study.
Randomization and interventions
The randomization list was generated by the interactive voice response system provider with a validated system that automated the random assignment of treatment groups. Novartis Drug Supply Management was responsible for producing a separate medication randomization list using a validated system that automates the random assignment of medication numbers to medication packs. Novartis supplied the investigators with all study medication. Placebo, drug tablets and capsules were matched for size, shape and colour to maintain blinding. Patients were instructed to take one tablet or capsule per dose from each of three provided bottles.
Outcomes and measurements
The primary end point was a non-inferiority change in msSBP from baseline to week 12 end point between aliskiren vs ramipril. If aliskiren was shown to be non-inferior to ramipril, superiority was tested. Secondary end points were the following: change from baseline in msSBP at week 36 end point with aliskiren-based therapy vs ramipril-based therapy; change from baseline in msDBP at weeks 12 and 36 end points; percentage of patients who achieved BP control (defined as a composite control rate of non-diabetic patients (msSBP/msDBP o140/ 90 mm Hg) and diabetic patients (o130/80 mm Hg)) at weeks 12 and 36 end points; percentage of patients who required add-on therapy; and safety and tolerability. Sitting and standing BP was measured at 24±3 h after dose, in accordance with the 2005 American Heart Association Committee on Blood Pressure Determination, 22 and recorded at all study visits (baseline and at weeks 2, 4, 8, 12, 16, 22, 28 and 36, or at discontinuation). At each study visit, after the patient had been sitting for 5 min, with back supported and both feet placed on the floor, BP was measured three times using a standard mercury sphygmomanometer and appropriate cuff size (cuff width approximately half the size of arm circumference).
Follow-up
Patients were monitored closely throughout the study and those who experienced msSBP of X180 mm Hg or msDBP of X110 mm Hg at any time, including the washout and run-in periods, were withdrawn from the study and appropriate therapy was instituted. Safety and tolerability assessments included the recording of all adverse events (AEs) and serious adverse events throughout the study, irrespective of suspected relation to study medication.
Statistical analysis
A sample size of 912 randomized patients, assuming a dropout rate of 15%, was targeted with equal randomization between treatment groups. For the primary efficacy variable, the null hypothesis that the aliskiren regimen was inferior to the ramipril regimen by a specified difference in BP (D) was tested against the alternative hypothesis that the aliskiren regimen was not inferior to the ramipril regimen by a specified D.
Data for msSBP and msDBP are reported as mean ± standard deviation (s.d.), unless otherwise specified. Changes from baseline in msSBP and msDBP were analysed using the intent-to-treat populations and these results are reported as the least squares mean (LSM) change from baseline ± standard error (s.e.). Last observation carried forward was used to impute missing values in patients who discontinued before week 12. The non-inferiority margin was pre-specified as 3.5 mm Hg in msSBP change. The statistical test was performed at a one-sided significance level of a ¼ 0.025. If the non-inferiority test was statistically significant, then the supplementary test to show superiority was also performed. The superiority statistical test was performed at the two-sided significance level of a ¼ 0.05. Both the non-inferiority and superiority statistical tests were performed using an analysis of covariance model with treatment regimen, age strata and region as factors and with baseline msSBP as covariate. The LSM difference between the treatment regimens for the change from the baseline in msSBP at week 12 was determined along with its 95% two-sided confidence interval (CI). For prespecified secondary end points assessing BP changes, the same procedures were used, including the use of last observation carried forward (at end points) to impute missing values. A difference of 2.0 mm Hg in msDBP was the non-inferiority margin. Changes from baseline in msSBP and msDBP at week 22 end point (data include last observation carried forward for patients who discontinued before week 22) were assessed and are included in this report. These analyses were not pre-specified in the protocol. This was the time point at which amlodipine could be added to the treatment. For the analysis of patients reaching BP goal, the analysis of patients requiring add-on amlodipine and the analysis of the proportion of patients requiring addon HCTZ, a logistic regression model with treatment regimen, age strata, and region as factors and baseline msSBP as covariate was performed at each time point. All statistical analyses were performed with SAS/STAT version 9.13 on Enterprise Guide version 4.1 (SAS Institute, Cary, NC, USA) and were the responsibility of the Novartis trial statistician (JB).
Results
Patient characteristics
Patient disposition throughout the trial is illustrated in Figure 1b . Patient demographics in the randomized population are shown in Table 1 . A total of 901 patients were randomized (aliskiren, n ¼ 457; ramipril, n ¼ 444). The mean age of all patients was 72.1 years (s.d., 5.6), 52.4% were women, 85.1% were Caucasian, 20.6% were having diabetes and 40.2% were obese (body mass index X30 kg m
À2
). Patients aged X75 years made up 32.5% of the total population.
Efficacy
The primary efficacy measure was the change in msSBP from baseline to week 12 end point. Aliskiren decreased msSBP from 156.5 ± 10.9 to 142.9 ± 18.0 mm Hg (LSM change from baseline of À14±0.8 mm Hg) (Figure 2a ). Ramipril decreased msSBP from 156.6 ± 10.6 to 145.3 ± 16.1 mm Hg (LSM change from baseline of À11.6 ± 0.8 mm Hg). The LSM difference in change from baseline between treatments was À2.3 mm Hg (95% CI, À4.3 to À0.3). Aliskiren monotherapy showed statistically non-inferior (Po0.001) and statistically superior (P ¼ 0.02) reductions in msSBP compared with ramipril monotherapy. At the week 22 end point, the aliskiren-based therapy decreased msSBP to 137.0±17.8 mm Hg (LSM change from baseline of À19.6 ± 0.8 mm Hg), whereas ramipril-based therapy decreased msSBP to 139.6 ± 16.8 mm Hg (LSM change from baseline of À17.3±0.8 mm Hg). The LSM difference in change from baseline between treatments was À2.4 mm Hg (95% CI, À4.5 to À0.3; P ¼ 0.03). At the week 36 end point, aliskiren-based therapy decreased msSBP to 136.5±17.3 mm Hg (LSM change from baseline of À20 ± 0.8 mm Hg), whereas ramipril-based therapy decreased msSBP to 138.5 ± 16.9 mm Hg (LSM change from baseline of À18.1 ± 0.8 mm Hg). The LSM difference in change from baseline between treatments was À1.9 mm Hg (95% CI, À4.0 to 0.2; P ¼ 0.07).
Aliskiren monotherapy decreased msDBP from a baseline measure of 85.5±9.4 to 80.7±10.7 mm Hg (LSM change from baseline of À5.1 ± 0.4 mm Hg) and ramipril decreased msDBP from a baseline of 86.0±9.0 to 82.5±9.6 mm Hg (LSM change from baseline of À3.6±0.4 mm Hg) at week 12 end point (Figure 2b ). The LSM difference in change from baseline between treatments was À1.5 mm Hg (95% CI, À2.6 to À0.5; Po0.01). At the week 22 end point, aliskiren-based therapy decreased msDBP to 77.8 ± 10.4 mm Hg (LSM change from baseline of À8.2±0.4 mm Hg), whereas ramipril-based therapy decreased msDBP to 78.9 ± 10.3 mm Hg (LSM change from baseline of À7.3 ± 0.4 mm Hg). The LSM difference in change from baseline between treatments was À0.8 mm Hg (95% CI, À2.0 to 0.3; P ¼ 0.14). At week 36 end point, aliskiren-based therapy decreased msDBP to 77.6±9.9 mm Hg (LSM change from baseline of À8.2±0.5 mm Hg), whereas the ramipril-based therapy decreased msDBP to 79.1 ± 9.8 mm Hg (LSM change from baseline of À7.0±0.4 mm Hg). The LSM difference in change from baseline was À1.2 mm Hg (95% CI, À2.3 to À0.1; P ¼ 0.03). In patients with stage 2 hypertension (msSBP X160 mm Hg at randomization; n ¼ 171 and 176 for aliskiren and ramipril intent-to-treat populations, respectively), the change from baseline at the week 12 end point in msSBP was À17.0 mm Hg for patients receiving aliskiren monotherapy and À15.3 mm Hg for patients receiving ramipril monotherapy (P ¼ 0.35). At the week 22 end point, the reduction for aliskiren-based therapy was À23.9 and À21.1 mm Hg for ramipril-based therapy (P ¼ 0.18). In the subset of patients with stage 2 hypertension who completed the study (n ¼ 127 for aliskiren and n ¼ 135 for ramipril), the change from baseline in msSBP at 22 weeks was À29.6 mm Hg for aliskiren and À26.4 mm Hg for ramipril (Po0.001 (non-inferiority), P ¼ 0.08 (superiority)). At week 36 end point, the changes for aliskiren-and ramipril-based therapy were À25.2 and À22.2 mm Hg, respectively (P ¼ 0.14).
At the week 12 end point the change from baseline (LSM) in msSBP in patients o75 years (n ¼ 309) receiving aliskiren was À13.9 and À13.8 mm Hg in patients X75 years (n ¼ 142). In the ramipril treatment group the change in msSBP in the o75 years age group (n ¼ 291) was À11.4 and À12.0 mm Hg in the X75 years group (n ¼ 148).
In white patients treated with aliskiren (n ¼ 383) the change from baseline in msSBP (mean±s.d.) at the week 12 end point was À13.7±16.4 mm Hg whereas in black patients (n ¼ 34) it was À10.1 ± 18.0 mm Hg. In the ramipril treatment group the change in msSBP was À11.2±15.3 and À13.2± 17.1 mm Hg for white (n ¼ 374) and black patients (n ¼ 38), respectively.
The percentage of patients achieving BP control (defined as a composite control rate of non-diabetic patients (msSBP/msDBP o140/90 mm Hg) and diabetic patients (o130/80 mm Hg)) was significantly greater with aliskiren monotherapy (42%) compared with ramipril monotherapy (33%) at week 12 (Po0.01; Figure 3a ). This trend continued through the study, such that a significantly greater proportion of patients achieved BP control with aliskiren-based (62%) compared with ramipril-based (50%) therapies at week 22 (Po0.001). Similar BP control rates were achieved with aliskiren-based (59%) compared with ramipril-based (51%) therapies at week 36 (P ¼ 0.01).
Optional add-on therapy with HCTZ could be added to the treatment regimens at week 12, and by week 36 a significantly greater percentage of patients receiving ramipril than aliskiren required additional HCTZ (56 vs 46%; Po0.01) (Figure 3b) . Similarly, a greater percentage of patients receiving ramiprilbased (16%) vs aliskiren-based (12%) anti-hypertensive therapies required add-on therapy with both HCTZ and amlodipine by week 36 (P ¼ 0.048).
More patients on the aliskiren-based treatment were receiving monotherapy (42%) than patients on the ramipril-based treatment (29%) at trial end. At week 36 the changes from baseline in sodium, potassium, blood urea nitrogen and estimated glomerular filtration rate were similar in the two treatment groups. (Table 2) The numbers of patients who had laboratory values that exceeded prespecified thresholds in potassium, creatinine and blood urea nitrogen values at any time during the study were low ( Table 3 ). The percentage of patients with abnormal values of blood urea nitrogen and creatinine was similar in each treatment regimen. The percentage of patients with decreased or increased potassium values was also similar in each treatment regimen.
Safety
Safety and tolerability data from the week 36 end point are shown in Table 4 . Overall, the severity and incidence of AEs were similar for the two treatment regimens, except cough. Significantly fewer patients reported cough with aliskiren-based (4.2%) than ramipril-based (13.3%) therapy (Po0.001). More discontinuations due to AEs were observed with ramipril-based (11.5%) compared with aliskirenbased therapy (7.1%). The most common AEs resulting in discontinuation were diarrhoea in the aliskiren group (1.1%) and cough in the ramipril group (3.6%). In the aliskiren group, the percentage of patients with orthostatic BP changes was fairly constant during the study, with a slight decrease in the percentage over the course of the study from 4.4% at baseline to 2.9% at week 36; there was a slight increase, from 2.9 to 3.9%, for the ramipril group.
Discussion
Age is a major risk factor for hypertension, stroke and heart failure. 23 The lifetime risk for development of hypertension among individuals 55 and 65 years of age in the Framingham Heart Study population was reported to be 90%. 24 Existing data suggest an overall benefit of drug therapy in the elderly to prevent stroke, hypertension and death, 7, 8, 11 even in patients 80 years of age or older. 25 The AGELESS study showed that aliskiren was both non-inferior and superior to the ACE inhibitor, ramipril, in lowering SBP and DBP as monotherapy over a 12-week period in elderly patients with systolic essential hypertension. Aliskiren-based therapy at 36 weeks was non-inferior to ramiprilbased therapy for lowering SBP, and lowering of DBP with aliskiren-based therapy was significantly superior to that observed with ramipril-based therapy. Significantly more patients reached target goal BP with an aliskiren-based than with the ramiprilbased regimen, and there was significantly less need for add-on therapy in the aliskiren-based regimen to reach BP goal. The findings herein provide additional information regarding the efficacy and safety of aliskiren in an elderly population. Although the AGELESS study was the first prospective study in that regard, a number of studies of aliskiren included elderly patients for whom the drug provided BP reduction and was well tolerated. 20, 26, 27 Two previous trials have compared aliskiren with ramipril. One study assessed the effects of aliskiren compared with ramipril or the agents combined for 8 weeks in patients with diabetes and hypertension. 28 Aliskiren monotherapy provided a superior reduction in msSBP compared with ramipril monotherapy. Combination therapy with aliskiren and ramipril provided superior msSBP reductions compared with either component monotherapy. Another doubleblind study compared long-term efficacy of aliskiren and ramipril alone and combined with HCTZ in patients with hypertension. 29 After 26 weeks, aliskiren-based therapy produced superior BP reductions and BP goal rates compared with ramiprilbased therapy. Both agents were well tolerated but more ramipril-treated patients had cough, which is similar to results seen in the AGELESS trial.
The AGELESS study indicated that there is less need for add-on therapy with aliskiren, which can be beneficial from therapeutic adherence as well as pharmacy use perspectives, considering that the elderly have many comorbid diseases and consequent polypharmacy. In patients with hypertension, medication non-adherence is a significant, often Table 2 Change from baseline in sodium, potassium, blood urea nitrogen and eGFR at week 36 unrecognized, risk factor that contributes to poor BP control, thereby contributing to the development of further cardiovascular disorders. 30, 31 Although this study was not designed to compare responses between age or race groups, the changes in msSBP at the 12-week end point induced by aliskiren and ramipril were numerically similar in the o75 and X75 years of age groups. Likewise the decreases in msSBP appeared to be similar in black and white patients although the low number of black patients enrolled in this study precludes a firm conclusion.
The results of this study are consistent with other studies with aliskiren showing an excellent tolerability profile when used in combination with HCTZ and amlodipine in elderly patients with hypertension. Based on previous findings and the pharmacokinetic profile of aliskiren, an intermediate and a high dosage were chosen for administration in this elderly population. 32 The doses of aliskiren used in this trial have been shown to be very well tolerated, with the incidence of AEs similar to those observed in a pooled analysis of the efficacy and safety of aliskiren. 33 There was low incidence of cough in the aliskiren group; however, this is a common AE with ACE inhibition and was also observed in this study.
Limitations of the study include those inherent in a non-inferiority trial, such as its applicability to other therapeutic approaches. Regarding the favourable response of aliskiren vs ramipril, it is theoretically possible that this was in part due to ramipril not being used at the highest dose of 20 mg per day; however, the rationale for dosing of ramipril at 10 mg per day is that it is the most commonly prescribed dosage. Moreover, we know from studies involving over 11 000 patients with hypertension where aliskiren has been extensively evaluated as monotherapy or combination therapy that the maximum dose of 300 mg has been shown to be relatively safe and well tolerated. 34 However, data on the long-term tolerability of aliskiren in the elderly population as well as in other patient populations are needed. In conclusion, the AGE-LESS study showed that direct renin inhibition with aliskiren had superior potency for lowering SBP and DBP, provided greater attainment of BP goal and required less add-on therapy compared with ramipril in elderly patients with systolic hypertension. What is known about this topic K In the United States, more than two-thirds of the population aged X65 years is hypertensive K The most common type of uncontrolled hypertension in the elderly is systolic hypertension that is associated with significant cardiovascular morbidity and mortality K To achieve blood pressure goals most patients require aggressive treatment with two or more anti-hypertensive agents from different drug classes
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What this study adds K The direct renin inhibitor, aliskiren, has not been prospectively evaluated in elderly patients with systolic hypertension K Aliskiren was both non-inferior and superior to the ACE inhibitor, ramipril in lowering systolic and diastolic BP in elderly patients with systolic hypertension K More patients reached target BP goal and there was less need for add-on therapy with aliskiren-based therapy than with ramipril-based therapy
